Pan-cancer clinical studies have revealed that apart from PD-L1 levels, mismatch repair deficiency, peripheral blood markers and high mutational and neoantigen load predict response to immune checkpoint inhibitors.39–42 These are all surrogate markers for tumours surrounded by active immune cells, or the so-called ‘hot’ tumours. Here, CD274 is linked to cancer.